Technological Advances in the Treatment of Type 1 Diabetes - karger - 9783318023367 -
Technological Advances in the Treatment of Type 1 Diabetes 

Technological Advances in the Treatment of Type 1 Diabetes

Achetez l'article neuf à prix reduit et gagnez 157 €

In 1993, the Diabetes Control Complications Trial (DCCT) study established that chronic hyperglycemia initiates and progresses to microvascular complications such as retinopathy in type 1 diabetes mellitus (T1DM). The milestone message from DCCT has been that early near-normalization of blood glucose in recent-onset T1DM with glycated hemoglobin (HbA1C) <7.0% [...]
[lire le résumé du livre]

Auteur : 

Editeur : Karger

Collection : Frontiers in Diabetes

Date parution :

 Bilingue : Français | Anglais


Reliure :
Relié
Nbr de pages :
263
Dimension :
19 X 30 cm
ISBN 10 :
3318023361
ISBN 13 :
9783318023367
190,00 €(-82%)   33,00 €
En stock en ligne
Expédié aujourd'hui 
A retirer en librairie à partir du 30/03 à 31,35€ -5%
Paiements sécurisés
CB Google/Apple Pay, Chèque, Virement
0.01€ à partir de 35€ en France métropolitaine
Satisfait ou remboursé sous 14 jours ouvrés

Quel est le sujet du livre "Technological Advances in the Treatment of Type 1 Diabetes"

In 1993, the Diabetes Control Complications Trial (DCCT) study established that chronic hyperglycemia initiates and progresses to microvascular complications such as retinopathy in type 1 diabetes mellitus (T1DM).

The milestone message from DCCT has been that early near-normalization of blood glucose in recent-onset T1DM with glycated hemoglobin (HbA1C) <7.0% prevents the appearance and delays progression of microvascular complications.

To achieve this, the physiological model of insulin substitution is needed with basal insulin for the fasting state and prandial insulin at each carbohydrate meal. This can be achieved with continuous subcutaneous insulin infusion (CSII), the gold-standard approach to substituting basal insulin, or multiple daily insulin injections (MDI) using long-acting insulin analogues as basal insulin (glargine or degludec once a day, detemir twice a day) with very similar results. Neutral protamine Hagedorn should be totally dismissed in the treatment of T1DM. It does not really matter whether CSII or MDI is used, as long as HbA1C is maintained <7.0% in each treatment. Unfortunately, only a minority of T1DM patients reach this target.

 To increase the success of intensive treatment, education of diabetologists, the diabetes team, and the diabetic subjects on how to use insulin, diet, and physical exercise are strongly needed.

En suivant ce lien, retrouvez tous les livres dans la spécialité Diabétologie.

Avis clients sur Technological Advances in the Treatment of Type 1 Diabetes - karger - Frontiers in Diabetes

(Ils sont modérés par nos soins et rédigés par des clients ayant acheté l'ouvrage)
Donnez votre avis
 
Controler les cookies